[Added entry for ARYX’s ATI-5923. Please see MNTA ‘ReadMeFirst’ for info on M118.]
General #msg-25160571 Anticoagulant market has large potential (WSJ) #msg-26899903 Anticoagulant market has large potential (graphic) #msg-26451612 Venous thromboembolism is a big, big problem (The Lancet) #msg-18759853 Overview of the new oral anticoagulants #msg-26701803 Technical overview of traditional anticoagulants
Rivaroxaban #msg-25147464 Rivaroxaban bests Lovenox in VTE prevention #msg-24337258 Bayer plans 50,000(!)-patient study
Apixaban #msg-19134406 PFE, BMY ink $1B collaboration #msg-21044973 Apixaban non-inferior to Warfarin in phase-2
Dabigatran #msg-26086079 BI completes enrollment of huge AF trial #msg-25152872 BI starts phase-2 in ACS #msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention
Miscellaneous #msg-27590644 ATI-5923 from ARYX: A safer warfarin? #msg-10569101 Arixtra bests Lovenox in ACS #msg-26298260 Biotinylated Idraparinux causes excess bleeding in AF #msg-22938795 SNY’s AVE5026, Otamixaban (SR123781 dropped Feb-08) #msg-27043616 ART-123 from Artisan Pharma #msg-27187973 Paion’s Solulin completes phase-1 #msg-26385806 NUVO’s NU172 starts phase-1
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.